Welcome to our dedicated page for Palisade Bio SEC filings (Ticker: PALI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Palisade Bio, Inc. (Nasdaq: PALI) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-assisted summaries to help interpret complex documents. As a clinical-stage biopharmaceutical company focused on autoimmune, inflammatory, and fibrotic diseases, Palisade Bio uses SEC filings to describe its development of once-daily, oral PDE4 inhibitor prodrugs, capital-raising activities, and corporate governance matters.
Through registration statements such as Form S‑1, investors can review detailed information about Palisade Bio’s business, risk factors, and public offerings of common stock and pre-funded warrants. These documents outline how the company intends to finance its clinical programs, including the advancement of its lead candidate PALI-2108 for ulcerative colitis and fibrostenotic Crohn’s disease. AI tools on this page can highlight key sections, such as use of proceeds, dilution, and summary business descriptions.
Current reports on Form 8‑K provide timely updates on material events. Recent 8‑Ks discuss topics such as Nasdaq minimum bid price compliance, the adoption and later termination of a Phantom Unit Plan for executives and directors, outcomes of annual meetings of stockholders, and the approval of a reverse stock split authorization within a specified ratio range. These filings also cover voting results, equity-based compensation arrangements, and other corporate actions relevant to shareholders.
Proxy statements on Schedule 14A offer further detail on director elections, auditor ratification, capital structure proposals, and special meeting agendas, including warrant-related share issuance approvals. On Stock Titan, AI-powered analysis can help users quickly identify the portions of these filings that address governance changes, executive arrangements, and share authorization requests. Together, the real-time feed of SEC documents and AI summaries enables a structured view of how Palisade Bio manages its capital structure, listing status, and development priorities for its gut-targeted PDE4 inhibitor prodrug platform.
RA Capital Management and affiliated entities reported a significant passive stake in Palisade Bio, Inc. They beneficially owned 15,746,829 shares of Palisade Bio common stock as of December 31, 2025, representing 9.99% of the outstanding class.
The RA Capital Healthcare Fund directly holds 7,124,116 shares of common stock and pre-funded warrants exercisable for up to 16,614,285 additional shares. A Beneficial Ownership Blocker in the warrants prevents exercises that would push aggregate ownership above 9.99% of the company’s common stock. For Section 13(d) purposes, RA Capital, Peter Kolchinsky, and Rajeev Shah may be deemed beneficial owners but expressly disclaim beneficial ownership outside regulatory reporting.
The ownership percentage is based on 149,003,210 shares outstanding as of November 5, 2025, plus 8,622,713 shares issuable upon warrant exercise. The filing also certifies that the securities are not held to change or influence control of Palisade Bio.
Palisade Bio, Inc. received an updated ownership filing showing that investment entities affiliated with Point72 report a significant passive stake in the company. As of the close of business on December 31, 2025, Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen collectively reported beneficial ownership of 10,495,252 shares of Palisade Bio common stock, representing 7.0% of the outstanding class. They report no sole voting or dispositive power, but shared voting and shared dispositive power over all these shares, which are held by Point72 Associates, LLC under an investment management agreement. The filing is made on a Schedule 13G/A basis, with the certifying party stating the securities were not acquired and are not held for the purpose of changing or influencing control of Palisade Bio.
Perceptive Advisors and affiliates reported a significant ownership position in Palisade Bio, Inc. The filing shows beneficial ownership of 15,200,117 shares of common stock, representing 9.99% of the class, including shares underlying pre-funded warrants.
The Master Fund directly holds 12,050,000 common shares and pre-funded warrants for 5,185,714 additional shares at an exercise price of $0.0001 per share, subject to a 9.99% beneficial ownership cap. Ownership percentages are based on 149,003,210 shares outstanding as of November 5, 2025. The reporting persons certify the holdings are not for the purpose of changing or influencing control of Palisade Bio.
Squadron Master Fund LP and related parties report beneficial ownership of 4,500,000 shares of Palisade Bio, Inc. common stock, representing 3.0% of the class. The stake is reported on a Schedule 13G/A as of an event date of 12/31/2025.
The ownership percentage is based on 149,003,210 shares of common stock outstanding as of November 5, 2025, as stated in Palisade Bio’s Form 10-Q filed November 10, 2025. Squadron Capital Management, LLC, as investment adviser to private funds including Squadron Master Fund LP, may be deemed a beneficial owner, and partners Matthew Sesterhenn and William Blank may also be deemed beneficial owners.
All report 0 shares with sole voting or dispositive power and 4,500,000 shares with shared voting and dispositive power. They certify the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Palisade Bio.
Jones Mitchell Lawrence reported multiple insider transaction types in a Form 4 filing for PALI. The filing lists transactions totaling 17,989 shares at a weighted average price of $1.75 per share. Following the reported transactions, holdings were 13,263 shares.
Finley John David reported multiple insider transaction types in a Form 4 filing for PALI. The filing lists transactions totaling 30,562 shares at a weighted average price of $1.75 per share. Following the reported transactions, holdings were 27,353 shares.
Palisade Bio, Inc. received an amended Schedule 13G/A from Deep Track Capital and related entities reporting that they now beneficially own 0 shares, or 0.00%, of the company’s common stock as of December 31, 2025.
Deep Track Capital, Deep Track Biotechnology Master Fund, Deep Track Special Opportunities Fund and David Kroin each report no voting or dispositive power over any Palisade Bio shares. The filing notes that the ownership calculation is based on 149,003,210 shares outstanding as of November 5, 2025, as disclosed in Palisade Bio’s prior quarterly report.
Jones Mitchell Lawrence reported acquisition or exercise transactions in this Form 4 filing.
Palisade Bio Chief Medical Officer Mitchell Lawrence Jones was granted 787,000 restricted stock units on February 9, 2026. Each RSU represents a contingent right to receive one share of Palisade Bio common stock, though the units may be settled in cash until sufficient shares are reserved under the 2021 Equity Incentive Plan.
The RSUs are scheduled to vest as to 1/6 of the award on July 6, 2026, with the remaining portions vesting quarterly over the following 10 quarters. Vesting depends on Jones maintaining continuous service with the company through each vesting date.
Palisade Bio, Inc. reported that CEO and CFO Finley John David acquired a grant of 2,011,000 Restricted Stock Units (RSUs) on February 9, 2026. Each RSU represents a right to receive one share of common stock, though the RSUs may be settled in cash until sufficient shares are reserved under the 2021 Equity Incentive Plan.
The RSUs will vest as to one-sixth of the units on July 6, 2026 and then vest quarterly over the following 10 quarters, conditioned on Finley’s continuous service with the company through each vesting date. Following this grant, he directly holds 2,011,000 derivative securities in the form of RSUs.